Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

"Switch" studies for people with lipodystrophy

    Project Inform Perspective
    |August 13, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Patients stopping protease inhibitors may lower cholesterol and triglyceride levels. However, evidence is conflicting on whether this approach effectively reverses HIV-associated lipodystrophy syndrome.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • HIV/AIDS management
    • Metabolic disorders
    • Pharmacological interventions

    Background:

    • Many individuals with HIV are discontinuing protease inhibitors (PIs) to address metabolic complications.
    • Concerns include reversing fat redistribution (lipodystrophy) and lowering elevated cholesterol and triglyceride levels.
    • These metabolic changes are often associated with long-term anti-HIV therapy.

    Discussion:

    • Studies indicate that omitting PIs can be effective in reducing triglyceride and cholesterol levels.
    • The efficacy of this strategy in reversing lipodystrophy syndrome remains uncertain, with mixed research findings.
    • This highlights a complex interplay between antiretroviral therapy and metabolic health.

    Key Insights:

    • Switching from protease inhibitor-based regimens shows potential for improving lipid profiles.

    Related Experiment Videos

  • The impact on lipodystrophy syndrome is variable and requires further investigation.
  • Patient-reported outcomes and long-term metabolic monitoring are crucial.

    • Outlook:

    • Further research is needed to clarify the long-term effects of PI-free regimens on body composition.
    • Personalized treatment strategies may be necessary to balance viral suppression and metabolic health.
    • Exploring alternative antiretroviral drug classes could offer better metabolic profiles.